Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of differentially expressed gene signature in ITLN1-treated ovarian cancer cells

ABSTRACT: Identification of differentially expressed gene signature in ITLN1-treated ovarian cancer cells

PROVIDER: PRJNA492289 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Identification of differentially expressed gene signature in ITLN1-treated ovarian cancer cells

Project description:Microarray analysis was used to identify differentially expressed gene signature in ovarian cancer A224 cells treated with recombinant human ITLN1 protein. MMP1 was found to be significantly upregulated in ITLN1-treated A224 cells. Further studies revealed that MMP1 is an important mediator for the ITLN1 suppression of ovarian cancer cell motility and invasion potential.

2019-09-20 | GSE120245 | GEO

Differentially expressed mRNA in biological premature ovarian insufficiency (bPOI)

Project description:Differentially expressed mRNA in biological premature ovarian insufficiency (bPOI)

| PRJNA830696 | ENA

Differentially expressed lncRNA in biological premature ovarian insufficient(bPOI)

Project description:Differentially expressed lncRNA in biological premature ovarian insufficient(bPOI)

| PRJNA665514 | ENA

Differentially expressed lncRNA in biological premature ovarian insufficiency (bPOI)

Project description:Differentially expressed lncRNA in biological premature ovarian insufficiency (bPOI)

| PRJNA559738 | ENA

Identification of differentially expressed transcription factors in ovarian cancer

Project description:Ovarian cancer is the fifth most common form of cancer in women in the United States. Epithelial ovarian cancer is the most common and is highly lethal. In 2014, there will be an estimated 21,980 new cases and 14,270 deaths from ovarian cancer in the United States. No major strides have been made to improve survival over the past decade. Ovarian cancer is notable for initial chemotherapy sensitivity (>75% response rates) using combination platinum and taxane chemotherapy following debulking surgery. However, eventually, the vast majority of these women (>75-80%) will have their cancer recur within 12 to 24 months after diagnosis and will die of progressively chemotherapy-resistant diseases. Transcription factors act as master switches of various biochemical pathways by regulating gene transcription. Large number of studies demonstrated the role of transcription factors in cancer development and progression. However, transcription factors involved in the pathogenesis of ovarian cancer have not been explored thoroughly. Therefore, we propose to using transcriptome profiling to generate a transcription factor gene signature for high-grade serous ovarian cancer.

2017-06-05 | GSE54388 | GEO

Differentially expressed miRNAs in serum of diminished ovarian reserve (DOR) patients

Project description:Differentially expressed miRNAs in serum of diminished ovarian reserve (DOR) patients

| PRJNA438138 | ENA

Identification of differentially expressed circRNAs in OLF

Project description:Identification of differentially expressed circRNAs in OLF

| PRJNA416002 | ENA

Identification of differentially expressed microRNAs in OLF

Project description:Identification of differentially expressed microRNAs in OLF

| PRJNA416005 | ENA

Differentially expressed miRNAs in serum of diminished ovarian reserve (DOR) patients

Project description:To investigate the pathogenesis of diminished ovarian reserve, differentially expressed miRNAs in serum were constructed through miRCURYTM LNA expression Array.

2018-03-14 | GSE111773 | GEO

Comparison of the differentially expressed genes in normal vs ovarian cancer cells

Project description:Comparison of the differentially expressed genes in normal vs ovarian cancer cells

| PRJNA432514 | ENA